Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Optimer Pharmaceuticals has announced that the US Patent and Trademark Office has issued a patent for claims covering a novel polymorphic form of the active pharmaceutical ingredient in the investigational drug candidate, OPT-80.
Subscribe to our email newsletter
The patent specifically claims the Form A polymorph of OPT-80, as well as all dosage forms and pharmaceutical compositions including the Form A polymorph of OPT-80. OPT-80 is currently in two Phase III clinical trials for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficile-associated disease, or CDAD.
According to Optimer, OPT-80 is a first in-class narrow spectrum antimicrobial agent with excellent activity against many clostridia including Clostridium difficile and moderate activity against certain gram-positive bacteria.
Michael Chang, president and CEO of Optimer, said: “Our scientists have determined that polymorphic Form A is the most stable crystalline form of OPT-80. We believe this patent, along with additional pending patent applications, will enhance our intellectual property protection for OPT-80.”